This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
NANOS3 / Nanos homolog 3 · IHC design guide
Design Immunohistochemistry for NANOS3
Plan chromogenic NANOS3 IHC on paraffin sections using testis spermatogonia as a positive reference (HPA tissue IHC). Start the catalog antibody at 2.5 μg/mL (datasheet) and assess nuclear and cytoplasmic staining as molecular expectations, since the tissue-IHC compartment is unconfirmed (UniProt; HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
NANOS3 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nucleus and cytoplasm expected; IHC compartment unconfirmed (UniProt) | |
| Staining pattern | Medium testis spermatogonia; low ovarian follicle cells; site unknown (HPA tissue IHC) | |
| Antigen retrieval | Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen) | |
| Positive control | Testis | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep paraffin-section fixation consistent across samples (standard IHC practice; not target-specific); Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A07449) | |
| Caveat | Oocyte staining cannot be correlated with the RNA-seq data (HPA tissue IHC) | |
| Regulation | Highest in oocytes across oogenesis (UniProt) | |
| Isoform / epitope | Two isoforms; no cleavage annotated; epitope coverage unknown (UniProt) |
Section 1
Recommended NANOS3 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by published NANOS3 staining protocols for human tissue, bovine ovary, and macaque testis (PMC3090199; PMC4846992; PMC13079449).
| Sample | Tissue sections; selected-image fixative not specified (standard IHC workflow) |
| Fixation | Image fixative and duration unreported (datasheet A07449); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0, 20 min at 95–98 °C (standard rule: nuclear antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-NANOS3, 2.5 μg/mL (datasheet A07449) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | NANOS3-positive staining in spermatogonia cells of testis (HPA tissue IHC: Medium). HPA tissue profile: Expression in spermatogonia in testis and ovarian follicles. No signal in the no-primary control. |
💡Decision noteStart with the page’s Tris-EDTA pH 9.0 retrieval; if staining is weak, compare the published citrate pH 6.0 method (PMC13079449).
Section 2
What Is the Expected NANOS3 Staining Pattern?
NANOS3 is a non-membrane protein reported in the nucleus and cytoplasm (UniProt P60323: localization, topology). In tissue IHC, expect expression in testicular spermatogonia and ovarian follicles (HPA tissue IHC: Enhanced). HPA reports medium staining in spermatogonia and low staining in ovarian follicle cells; UniProt also reports expression in oocytes and several germ-cell stages (HPA tissue IHC; UniProt P60323: tissue specificity).
| Spermatogonia stain at medium intensity in testis; ovarian follicle cells show weaker staining. | This matches the cell-specific HPA tissue IHC observations (HPA: medium in spermatogonia; low in ovarian follicle cells). Assess cell identity alongside intensity: UniProt reports other germ-cell stages, but the supplied HPA positive-cell entry specifically identifies spermatogonia (UniProt P60323: tissue specificity; HPA tissue IHC). |
| Signal is confined to cell borders or forms a membrane-like rim. | Treat a membrane-only pattern as suspect: NANOS3 has no transmembrane segment and is assigned to the nucleus and cytoplasm (UniProt P60323: topology, localization). Recheck morphology and the detection controls before scoring it as NANOS3; HPA ICC-IF supports nucleoplasm and cytosol, though that does not prescribe an identical IHC appearance (HPA subcellular). |
| Strong staining appears in cells listed as negative, such as adipocytes in adipose tissue. | Investigate specificity or detection background before calling those cells positive (HPA tissue IHC: adipocytes not detected; general IHC practice). A negative HPA observation is a comparison point, not proof that every specimen must be blank. Check whether staining follows tissue structures or also appears in a no-primary control (general IHC practice). |
| Brown signal spreads across most cells, extracellular areas, or the entire section. | Diffuse signal obscures the selective spermatogonial pattern reported in testis (HPA tissue IHC: medium in spermatogonia). Review blocking, washes, antibody concentration, and detection controls as general IHC background checks (general IHC practice). Distribution alone cannot identify which step caused the background. |
| No staining is visible in testicular spermatogonia expected to be positive. | First verify that spermatogonia are present in the section; HPA reports medium staining in those cells (HPA tissue IHC). If they are present, review the catalog antibody’s IHC-P instructions and run the recommended controls (general IHC practice). An unstained section alone cannot distinguish technical failure from a specimen-specific result. |
💡Expected NANOS3 appearanceA convincing IHC positive shows cell-associated staining in testicular spermatogonia at about medium intensity, with weaker ovarian follicle-cell staining as a secondary comparison; a membrane-only rim or broad staining of HPA-negative cells warrants investigation (HPA tissue IHC; UniProt P60323: topology, localization).
| Cell type and tissue | HPA identifies medium staining in testicular spermatogonia and low staining in ovarian follicle cells (HPA tissue IHC). UniProt reports strongest ovarian expression in oocytes, but HPA says oocyte protein expression cannot be correlated with its RNA samples because that cell type is absent from them (UniProt P60323: tissue specificity; HPA: reliability description). |
| Subcellular comparison | UniProt assigns NANOS3 to nucleus, cytoplasm, stress granules, and P-bodies (UniProt P60323: localization). HPA ICC-IF supports a mainly nucleoplasmic location with additional cytosol (HPA subcellular). Use those assignments to assess plausibility, while recognizing that an ICC-IF image does not establish the visibility of small cytoplasmic structures in chromogenic IHC. |
| Antibody validation | HPA lists HPA062989 as IHC Enhanced and ICC Supported, and CAB080164 as IHC Supported with no ICC status supplied (HPA antibodies). The tissue profile has Enhanced reliability (HPA tissue IHC). These labels support comparison with the reported pattern; they do not establish the performance of an unspecified catalog antibody. |
| Isoforms and epitope coverage | UniProt lists two NANOS3 isoforms, while the supplied record gives no antibody epitope or isoform-specific validation (UniProt P60323: isoforms; HPA antibodies). Do not assign a staining difference to one isoform without antibody-specific evidence. NANOS3 is annotated as a 1–173 chain with no signal peptide or propeptide (UniProt P60323: processing). |
| Detection background | For chromogenic IHC, endogenous detection activity and incomplete blocking can produce signal independent of primary-antibody binding (general IHC practice). Use a no-primary control to assess that possibility. This is a general workflow factor, not an HPA or UniProt finding about NANOS3. |
| Situation | Likely cause | Next action |
|---|---|---|
| Testis shows no signal where spermatogonia are visible. | The expected comparison is medium spermatogonial staining (HPA tissue IHC); the image alone does not identify the failed step. | Confirm cell identity, check the catalog antibody’s IHC-P instructions, and compare with processing and detection controls (general IHC practice). Do not infer NANOS3 absence from one negative section. |
| Ovary appears weak beside testis. | HPA reports low staining in ovarian follicle cells versus medium staining in testicular spermatogonia (HPA tissue IHC). | Score the relevant cell populations separately (general IHC practice). Do not use the HPA RNA comparison to discount oocyte protein expression: oocytes were absent from its RNA samples (HPA: reliability description). |
| A membrane rim is the dominant pattern. | That distribution conflicts with the reported nuclear and cytoplasmic localization and lack of a transmembrane segment (UniProt P60323: localization, topology). | Inspect compartment boundaries at higher magnification and compare detection controls (general IHC practice). Treat the rim as unconfirmed until a cell-associated pattern is resolved. |
| Many unrelated cells or tissue spaces are brown. | Broad staining differs from the selective HPA tissue pattern (HPA tissue IHC); background has several possible technical causes (general IHC practice). | Compare a no-primary control, then review blocking, washes, and antibody concentration under the catalog IHC-P instructions (general IHC practice). Change one condition at a time. |
| Adipocytes in adipose tissue show strong staining. | HPA lists those adipocytes as not detected, so the result conflicts with that reference observation (HPA tissue IHC). | Verify cell identity and assess a no-primary control before interpreting the signal as NANOS3 (general IHC practice). Record any persistent difference as specimen and antibody dependent. |
| IF/ICC: where should cellular signal appear? | HPA reports mainly nucleoplasmic signal with additional cytosol in ICC-IF; UniProt also lists nuclear and cytoplasmic localization (HPA subcellular; UniProt P60323: localization). | Use those compartments as the IF/ICC interpretation reference, and consult the separate IF/ICC guide for that application (HPA subcellular; general IHC/IF practice). |
Experiment evidence
IHC & IF images showing NANOS3 staining
A07449 · IHCImmunohistochemistry of Nanos3 in human brain tissue with Nanos3 antibody at 2.5 μg/mL.
A07449 · IFImmunofluorescence of Nanos3 in Human Brain tissue with Nanos3 antibody at 20 μg/mL.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000187556-NANOS3/tissue/cerebral+cortex#imid_20199879
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000187556-NANOS3/tissue/colon#imid_20199789
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000187556-NANOS3/tissue/liver#imid_20199806
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000187556-NANOS3/tissue/kidney#imid_20199807
HPA · ICC-IF A-549Human Protein Atlas immunofluorescence, A-549, antibody HPA062989; green = NANOS3, blue = nucleus, red = microtubules.
HPA · ICC-IF A-549Human Protein Atlas immunofluorescence, A-549, antibody HPA062989; green = NANOS3, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for NANOS3 IHC & IF
🧪Run testis first: spermatogonia must show staining (HPA: Medium in spermatogonia). Use adipose tissue as a negative, with adipocytes expected to remain unstained (HPA: Not detected in adipocytes); on the testis slide, assess adjacent non-spermatogonial cells for background staining rather than treating them as a proven negative population (HPA: positive assignment limited to spermatogonia).
Positive control tissue: Testis (Spermatogonia cells, HPA Medium)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show NANOS3 in A-549, SH-SY5Y, U2OS, with annotated localisation: Nucleoplasm (supported) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control and an isotype control matched to the primary antibody’s host species and clonality; confirm specificity with NANOS3 knockout material or peptide competition if a suitable peptide is available (standard IHC control practice). For chromogenic testis IHC, block endogenous peroxidase and, if using biotin-based detection, assess endogenous biotin (standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect and antigen-retrieval dependency are unreported in the supplied evidence; optimize retrieval for the paraffin-section assay (supplied target/application evidence; standard IHC practice). The selected A07449 brain IHC caption reports 2.5 μg/mL but leaves the fixative unreported (selected-SKU caption). The evidence does not establish whether frozen sections or IF are easier; varied germ-cell stages in testis can complicate interpretation of staining across tubules (UniProt tissue specificity).
HPA tissue IHC evidence for NANOS3
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Protein expression in oocytes cannot be correlated with RNA expression data due to cell type not present in RNA-seq samples.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Testis | Spermatogonia cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced NANOS3 IHC Tips
Troubleshoot NANOS3 staining in paraffin sections using the catalog antibody’s brain tissue image, the page retrieval setting, and independent expression and localisation evidence.
How should I retrieve NANOS3 in paraffin sections when nuclear staining is weak?
Use Tris-EDTA at pH 9.0 for heat-induced epitope retrieval at 95–98 °C for 20 min (page retrieval setting). Allow sections to cool in retrieval buffer, then compare them with an identically processed positive control before changing antibody concentration (standard IHC practice). If staining remains weak, compare a shorter heating time on adjacent sections while keeping the stated buffer and pH as the reference condition (standard IHC practice). Score nuclear and cytoplasmic signal separately because both compartments are reported for NANOS3 (UniProt P60323; HPA subcellular). Excessive heating can damage morphology and make apparent signal difficult to assign to individual cells (standard IHC practice).
Could fixation explain weak or uneven NANOS3 staining?
Target-specific sensitivity of NANOS3 to fixation is unknown from the supplied evidence; the catalog brain tissue caption does not state a fixative (catalog image A07449). Record fixation conditions and processing history for each specimen before comparing staining intensity across sections (standard IHC practice). Keep section thickness, retrieval, antibody incubation and chromogen development consistent when testing specimens with different fixation histories (standard IHC practice). Include a known positive tissue section in each run, using spermatogonia as a documented cellular reference where available (HPA tissue IHC: medium in testis spermatogonia). Do not attribute a weak result to fixation alone without checking tissue preservation, retrieval performance and control staining (standard IHC practice).
Which staining compartments should I score as plausible NANOS3 signal?
Evaluate nuclear and cytoplasmic staining separately: NANOS3 is reported in both compartments, with supported nucleoplasmic and additional cytosolic localisation (UniProt P60323; HPA subcellular). Fine cytoplasmic puncta may be biologically plausible because NANOS3 is reported in stress granules and P-bodies (UniProt P60323 subcellular). On chromogenic sections, require puncta to be distinguishable from precipitated chromogen before assigning that pattern (standard IHC practice). Record the stained cell type and compartment together, particularly in testis where spermatogonia show medium expression (HPA tissue IHC). An isolated extracellular deposit or signal confined to damaged section edges needs control review before being counted as intracellular staining (standard IHC practice).
How can epitope uncertainty affect interpretation across NANOS3 specimens?
NANOS3 has 2 listed isoforms, but the supplied antibody evidence does not identify the recognised epitope or establish isoform coverage (UniProt P60323; catalog image A07449). Check the antibody’s documented immunogen or epitope before interpreting a negative section as absence of every isoform (standard IHC practice). The record describes a 1–173 chain, with no signal peptide, transmembrane segment, annotated glycosylation site or modified residue (UniProt P60323). Those annotations do not establish which epitope survives paraffin processing or retrieval in a given specimen (UniProt P60323; standard IHC practice). Compare sections under identical retrieval and detection conditions, and report the antibody identity alongside any isoform-level limitation (standard IHC practice).
How should I corroborate a NANOS3 IHC pattern with multiplex IF?
On the separate IF/ICC guide, pair NANOS3 with a validated marker for the expected cell population, such as a spermatogonial marker when examining testis (HPA tissue IHC: medium in spermatogonia; standard IF practice). Select spectrally separated fluorophores and favour a longer-wavelength NANOS3 channel if tissue autofluorescence obscures shorter wavelengths (standard IF practice). Include single-label and no-primary controls to identify bleed-through and background before interpreting overlap (standard IF practice). NANOS3 has no transmembrane segment and is reported in nuclear and cytoplasmic compartments, so permeabilisation must permit intracellular epitope access (UniProt P60323; standard IF practice). Assess nuclear and cytoplasmic signals separately, including possible cytoplasmic puncta, when comparing IF with chromogenic IHC (UniProt P60323 subcellular).
What controls help distinguish NANOS3 staining from chromogenic background?
Run a no-primary control alongside a positive tissue section to assess detection-system background in the same staining run (standard IHC practice). Block endogenous peroxidase before an HRP and DAB workflow, and inspect any residual pigment or precipitate in the no-primary section (standard IHC practice). Review adipocytes in adipose tissue as one possible negative cellular reference because NANOS3 was not detected there by HPA tissue IHC (HPA tissue IHC). Avoid calling every brown deposit positive: score intracellular staining only when cell boundaries and morphology support that assignment (standard IHC practice). If background rises across both control and test sections, revisit blocking, wash steps and chromogen development before changing retrieval (standard IHC practice).
How should I quantify NANOS3 staining without masking cell-type differences? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and compartment before scoring; spermatogonia are a documented positive population, whereas HPA reports no detection in adipose tissue adipocytes (HPA tissue IHC). Report the percentage of positive target cells and staining intensity separately, or use an H-score on the conventional 0–300 scale (standard IHC scoring practice). For spatial comparisons, count positive cells per mm² of viable tissue and record the total target-cell count (standard IHC quantification practice). Normalise positive-cell counts to the number of evaluable cells of the same type, not all cells in a mixed section (standard IHC quantification practice). Keep imaging, threshold and chromogen development settings consistent across specimens, and exclude torn or necrotic regions from scoring (standard IHC practice).
When is a NANOS3-positive IHC result credible rather than artefactual?
A credible result places intracellular signal in anatomically identifiable cells and agrees with a positive control processed in the same run (standard IHC practice). In testis, staining of spermatogonia has direct support, while NANOS3 is also reported across additional germ-cell stages by UniProt (HPA tissue IHC; UniProt P60323 tissue specificity). Nuclear or cytoplasmic signal is plausible, including cytoplasmic granule-associated localisation, but a compartment alone does not prove antibody specificity (UniProt P60323 subcellular; HPA subcellular). Treat staining limited to section edges, necrosis, extracellular deposits or no-primary control areas as possible artefact (standard IHC practice). Review endogenous peroxidase blocking and DAB development if brown signal appears in unexpected cells or controls (standard IHC practice).
Boster reagents
Best NANOS3 / Nanos homolog 3 IHC Antibodies
A07449 supports IHC-P and IF (catalog: applications), with images of human brain tissue for each (catalog: IHC and IF captions); listed reactivity includes human, mouse, and rat (catalog: reactivity).
Real IHC data
Anti-Nanos homolog 3 Nanos3 Antibody
Cat # A07449
A07449 will render with a human brain tissue IHC image at 2.5 μg/mL (A07449 IHC caption). A07449 also has a human brain tissue IF image at 20 μg/mL (A07449 IF caption).
Which to pick: For paraffin-section tissue IHC, choose A07449 because IHC-P is listed (catalog: applications); its IHC caption shows human brain tissue at 2.5 μg/mL but does not report the fixative (A07449 IHC caption). For IF, choose A07449 based on its human brain tissue IF image at 20 μg/mL (A07449 IF caption); ICC validation is unreported (catalog: applications). For mouse or rat studies, A07449 lists reactivity with both species, although the supplied IHC and IF images show human tissue (catalog: reactivity; A07449 IHC and IF captions); its host is rabbit and clonality is unreported (catalog: host and clone).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P60323 (NANO3_HUMAN, Nanos homolog 3).
- Human Protein Atlas. NANOS3 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. NANOS3 subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to the cytosol..
- Human Protein Atlas. NANOS3 antibody validation summary (2 antibodies).
- NANOS3 function in human germ cell development. Human molecular genetics 2011 — PMC3090199.
- Nanos3, a cancer-germline gene, promotes cell proliferation, migration, chemoresistance, and invasion of human glioblastoma. Cancer cell international 2020 — PMC7249350.
- Generation of exogenous germ cells in the ovaries of sterile NANOS3-null beef cattle. Scientific reports 2016 — PMC4846992.
- The topographical distribution of spermatogonial subpopulations during the cycle of seminiferous epithelium in Macaca Fascicularis. Biology of reproduction 2026 — PMC13079449.
- PubMed PMID:15057824 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
- PubMed PMID:8889548 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for NANOS3 (Nanos homolog 3). Expected localisation Nucleus and cytoplasm expected; IHC compartment unconfirmed (UniProt). Antigen retrieval: Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen). Validated IHC antibody: A07449 at 2.5 μg/mL (the product's own IHC validation image is shown). Controls (HPA): positive Testis (Spermatogonia cells); negative Adipose tissue. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Tissue sections; selected-image fixative not specified (standard IHC workflow); 2. Fixation: Image fixative and duration unreported (datasheet A07449); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-NANOS3, 2.5 μg/mL (datasheet A07449); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep paraffin-section fixation consistent across samples (standard IHC practice; not target-specific); Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A07449); Caveat: Oocyte staining cannot be correlated with the RNA-seq data (HPA tissue IHC); Isoform / epitope: Two isoforms; no cleavage annotated; epitope coverage unknown (UniProt); Regulation: Highest in oocytes across oogenesis (UniProt). Evidence: UniProt P60323, HPA tissue IHC · Enhanced, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to the…, Datasheet A07449, PMC3090199, PMC4846992. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/NANOS3/immunohistochemistry-ihc-guide.